Moderna shares surged after positive Phase 3 results for its Merck-partnered melanoma cancer vaccine, boosting confidence in its portfolio beyond Covid-19.
Moderna has been saying for years that it would diversify its portfolio beyond infectious diseases. Investors were waiting for late-stage proof.
On Wednesday, they got …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Moderna and Merck shares soar on mRNA cancer vaccine
Moderna's and Merck's personalized mRNA vaccine shows real promise against deadly skin cancer melanoma in late stage trial and sends stocks soaring | Fortune
Moderna and Merck cancer vaccine returns ‘landmark’ result in melanoma
Moderna shares nearly triple on skin cancer vaccine success
Health Care Up After Moderna Breakthrough — Health Care Roundup
Moderna shares double after experimental mRNA cancer treatment passes key test
Moderna, Merck breakthrough could usher in a wave of cancer vaccines
First personalized mRNA cancer vaccine succeeds in Phase 3 trial
‘Breakthrough’ mRNA cancer drug curbs melanoma in large trial
mRNA’s second act: A bespoke cancer vaccine & what Merck-Moderna’s melanoma trial could mean for oncology
The results come at a pivotal moment for Moderna and mRNA research.
The shot, paired with Merck's Keytruda, cut the risk of melanoma recurrence in a trial of more than 1,100 patients.
At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning and…
The experimental therapy, jointly developed with Merck, would be unprecedented in cancer treatment, providing a custom-made…
Moderna reports five-year melanoma trial results with Merck and expands its Ebola vaccine partnership with CEPI, but MRNA stock…
Health-care companies rose after a breakthrough at the intersection of vaccines and oncology.
